Skip to main content

Table 1 Clinicopathological data according to A-FABP expression

From: Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up

  N(%) A-FABP P
Negative Positive
Population 236 (100) 134 (56.8) 102 (43.2)
Sex
 Male 192 (81.4) 111 (82.8) 81 (79.4) 0.503
 Female 44 (18.6) 23 (17.2) 21 (20.6)  
Age
 Mean (sd) 70.45 (±13.3) 72.1 (±12.8) 68.3 (±13.8) 0.028
Histology
 Papillary 215 (91.1) 118 (88.1) 97 (95.1) 0.06
 Variants* 21 (8.9) 16 (11.9) 5 (4.9)  
pT
 pTa 114 (48.4) 43 (32.1) 71 (69.6) < 0.001**
 pT1 61 (25.8) 39 (29.1) 22 (21.6)  
 pT2 45 (19.1) 40 (29.9) 5 (4.9)  
 pT3 5 (2.1) 4 (3.0) 1 (1.0)  
 pT4 11 (4.7) 8 (6.0) 3 (2.9)  
pN
 0 206 (87.3) 110 (82.1) 96 (94.1) 0.006
 1–2 30 (12.7) 24 (17.9) 6 (5.9)  
pM
 0 231 (97.9) 130 (97) 101 (99) 0.393
 1 5 (2.1) 4 (3) 1 (1)  
Grade
 PUNLMP 25 (10.6) 6 (4.5) 19 (18.6) < 0.001
 LG-UC 76 (32.2) 30 (22.4) 46 (45.1)  
 HG-UC 135 (57.2) 98 (73.1) 37 (36.3)  
Cis
 yes 9 (3.8) 7 (5.2) 2 (2) 0.306
 no 227 (96.2) 127 (94.8) 100 (98)  
  1. *The histological variants include micropapillary, nested, reversed and sarcomatoid variants, urothelial carcinoma with squamous, glandular or neuroendocrine differentiation
  2. **Due to some reduced numbers, the pT3 and pT4 stages were grouped together with the pT2 stage for the Khi-2 test
  3. Abbreviations: PUNLMP Papillary urothelial neoplasm of low malignant potential, LG-UC Low grade urothelial carcinoma, HG-UC High grade urothelial carcinoma, Cis Carcinoma in situ
\